(P107) Vero SBRT Treatment of Moving Lung Tumors

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Overall, 40%-thresholded 18F-FDG PET contours nonsignificantly enlarge PTVs when multiphase free-breathing, inspiration, and expiration breath-hold scans are used for Vero SBRT. Whether 18F-FDG PET contours improve local control of moving lung tumors treated by Vero SBRT needs further study.

Charles A. Kunos, MD, PhD, John P. Shanahan, MS; Summa Cancer Institute

PURPOSE: Intrafraction motion management of moving lung tumors during stereotactic ablative body radiotherapy (SBRT) remains challenging. We investigated whether 40%-thresholded 2-[18F] fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET) images enhanced intrafraction tracking capabilities of the Vero SBRT platform.

MATERIALS AND METHODS: Three patients with six total moving lung tumors had gross tumor volume (GTV) contours created on free-breathing, end-inspiration, and end-expiration breath-hold computed tomography (CT) images. A thresholded 40% maximum standard uptake value 18F-FDG PET contour was generated. The four individual contours contributed to a single image-guided internal target volume (ITV). Vero SBRT treatment planning was conducted on the free-breathing CT dataset, with the ITV expanded all around by 5 mm for a final planning target volume (PTV). The prescription for each lesion was 40 Gy in four fractions of 10 Gy given every other day. Non-coplanar radiation doses were determined using a Monte Carlo algorithm. T-test statistics were calculated to compare parameter means.

RESULTS: The PTV was 23 cm3 on average (standard deviation [SD] = 18 cm3) without the 18F-FDG PET contour and 36 cm3 on average (SD = 32 cm3) with the 18F-FDG PET contour (P = .41). The lung V20 Gy was 2.6% on average (SD = 0.9%) without the 18F-FDG PET contour and 2.8% on average (SD = 0.5%) with the 18F-FDG PET contour (P = .68). Vero SBRT gimbal pan-and-tilt range of 4 cm was not exceeded by the addition of the 18F-FDG PET contour to the ITV.

CONCLUSIONS: Overall, 40%-thresholded 18F-FDG PET contours nonsignificantly enlarge PTVs when multiphase free-breathing, inspiration, and expiration breath-hold scans are used for Vero SBRT. Whether 18F-FDG PET contours improve local control of moving lung tumors treated by Vero SBRT needs further study.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Related Content